Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/121768
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Title

Screening of effective pharmacological treatments for MELAS syndrome using yeasts, fibroblasts and cybrid models of the disease

AuthorsGarrido-Maraver, Juan; Cordero, Mario D. CSIC ORCID; Domínguez-Moñino, Irene CSIC ORCID; Pereira-Arenas, Sheila; Lechuga-Vieco, Ana V.; Cotán, David CSIC; Mata, Mario de la CSIC ORCID; Oropesa-Ávila, Manuel; Miguel, Manuel de; Bautista Lorite, Juan; Rivas Infante, Eloy; Álvarez-Dolado, Manuel CSIC ORCID CVN; Navas, Plácido CSIC ORCID; Jackson, Sandra; Sánchez-Alcázar, José Antonio CSIC ORCID
KeywordsCoenzyme Q10
Riboflavin
Mitochondrial disease
MELAS
Mitophagy
Issue Date19-Oct-2012
PublisherJohn Wiley & Sons
CitationBritish Journal of Pharmacology 167 (16): 1311-1328 (2012)
Abstract[Backgroun and Purpose]: MELAS (mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes) is a mitochondrial disease most usually caused by point mutations in tRNA genes encoded by mitochondrial DNA (mtDNA). Approximately 80% of cases of MELAS syndrome are associated with a m.3243A > G mutation in the MT-TL1 gene, which encodes the mitochondrial tRNALeu (UUR). Currently, no effective treatments are available for this chronic progressive disorder. Treatment strategies in MELAS and other mitochondrial diseases consist of several drugs that diminish the deleterious effects of the abnormal respiratory chain function, reduce the presence of toxic agents or correct deficiencies in essential cofactors.
[Experimental Approach]: We evaluated the effectiveness of some common pharmacological agents that have been utilized in the treatment of MELAS, in yeast, fibroblast and cybrid models of the disease. The yeast model harbouring the A14G mutation in the mitochondrial tRNALeu(UUR) gene, which is equivalent to the A3243G mutation in humans, was used in the initial screening. Next, the most effective drugs that were able to rescue the respiratory deficiency in MELAS yeast mutants were tested in fibroblasts and cybrid models of MELAS disease.
[Key Results]: According to our results, supplementation with riboflavin or coenzyme Q10 effectively reversed the respiratory defect in MELAS yeast and improved the pathologic alterations in MELAS fibroblast and cybrid cell models.
[Conclusions and Implications]: Our results indicate that cell models have great potential for screening and validating the effects of novel drug candidates for MELAS treatment and presumably also for other diseases with mitochondrial impairment.
DescriptionTrabajo presentado como póster al 22nd IUBMB & 37th FEBS Congress, celebrado en Sevilla (España) del 4 al 9 de septiembre de 2012.
Publisher version (URL)http://dx.doi.org/10.1111/j.1476-5381.2012.02086.x
URIhttp://hdl.handle.net/10261/121768
DOI10.1111/j.1476-5381.2012.02086.x
ISSN0007-1188
E-ISSN1476-5381
Appears in Collections:(CABD) Artículos
(CABIMER) Artículos




Files in This Item:
File Description SizeFormat
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work

PubMed Central
Citations

14
checked on Aug 18, 2022

SCOPUSTM   
Citations

34
checked on Aug 12, 2022

WEB OF SCIENCETM
Citations

28
checked on Aug 12, 2022

Page view(s)

307
checked on Aug 19, 2022

Download(s)

81
checked on Aug 19, 2022

Google ScholarTM

Check

Altmetric

Dimensions


Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.